SHL Telemedicine FY Sales $57.1M Up From $55.4M YoY
Save time and jump to the most important pieces.
SC 13G - SHL TELEMEDICINE LTD (0001166834) (Subject)
Users in Israel will be able for the first time in the world to perform an at-home Biomarker blood test guided by SHL's medical team, following ECG tests using The SmartHeart® for Rapid Heart Attack Detection.
Gainers Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shares rose 43.54% to $15.79. The company's market cap stands at $411.3 million. As per the news, the Q1 earnings report came out yesterday. BioRestorative Therapies (NASDAQ:BRTX) shares moved upwards by 16.93% to $1.45. The company's market cap stands at $9.8 million. Vaccinex (NASDAQ:VCNX) shares moved upwards by 15.72% to $6.77. The company's market cap stands at $10.7 million. Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 14.19% to $8.61. The market value of their outstanding sha
6-K - SHL TELEMEDICINE LTD (0001166834) (Filer)
6-K - SHL TELEMEDICINE LTD (0001166834) (Filer)
6-K - SHL TELEMEDICINE LTD (0001166834) (Filer)
David Arnon held senior leadership and CEO roles within the healthcare insurance industry at Harel Insurance and Clal Insurance, two of the largest insurance groups in Israel SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has announced today that it has appointed Mr. David Arnon as CEO of the Company. He will join SHL Telemedicine and assume the role on August 6, 2024, succeeding Erez Nachtomy, who, as previously announced, will step down as CEO. Mr. Arnon has over 17 years of commercial and executive level management experience within the healthcare insurance industry in Israel.
David Arnon held senior leadership and CEO roles within the healthcare insurance industry at Harel Insurance and Clal Insurance, two of the largest insurance groups in Israel SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has announced today that it has appointed Mr. David Arnon as CEO of the Company. He will join SHL Telemedicine and assume the role on August 6, 2024, succeeding Erez Nachtomy, who, as previously announced, will step down as CEO. Mr. Arnon has over 17 years of commercial and executive level management experience within the healthcare insurance industry in Israel.
SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has clarified today that it is in discussions with Discount Capital Ltd. the investment arm of Israel Discount Bank, regarding a possible investment relating to SHL's Israeli activity. At this point, the parties have not yet taken any decision nor entered into any binding obligation with regard to the realization of such transaction. SHL will further inform the market as required. About SHL Telemedicine SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center service
Users in Israel will be able for the first time in the world to perform an at-home Biomarker blood test guided by SHL's medical team, following ECG tests using The SmartHeart® for Rapid Heart Attack Detection. SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is proud to announce that it has expanded its offering in Israel to include the groundbreaking ability to perform at-home Biomarker blood tests. This diagnostic tool is designed to rapidly identify cardiac markers for detection of a heart attack, transforming emergency cardiac care with speed and precision. Following concerns o
SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX Swiss Exchange: SHLTN))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for the full-year 2023, highlighting fiscally responsible growth across all regions and a strategic focus on expansion and innovation. In 2023, SHL Telemedicine achieved key highlights, underscoring its global market strength. SHL's Israel operation maintained stability and profitability, reflecting the company's solid foundation in its home market. In the US, significant advancements were made toward launching direct-to-consumer (B2C) sales of the SmartHeart® ECG platform, enhancing access to r
SHL Telemedicine Ltd. ((SIX Swiss Exchange: SHLTN, NASDAQ:SHLT) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, today announced that it will publish its results for 2023 on Wednesday, April 17, 2024 at 7 am CET. The conference call for investors, journalists, and analysts to discuss the annual results 2023 will be hosted by Yariv Alroy, Chairman, Erez Nachtomy, CEO, and Amir Hai, CFO, and has been scheduled for the same day as following: Date: Wednesday, April 17, 2024 Time: 4 pm CET / 10 am ET / 5 pm Israel Time The conference call can be accessed live via the below dial-in numbers: From Europe +41 (0) 58 310 5
Regulatory News: SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX Swiss Exchange: SHLTN))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for half-year 2023, emphasizing stable revenues and strategic growth initiatives. In H1 2023, SHL maintained stable revenues while making significant strategic advancements across all operations. The Company made substantial investments in Germany, where it launched the Doctors' Virtual Visits services and then witnessed a steady increase in the adoption of the service. In the US, the Company witnessed the growing utilization and distribution of the SmartHeart® ECG platform by